title: A randomized trial of ciprofloxacin versus cefixime for treatment of gonorrhea after rapid emergence of gonococcal ciprofloxacin resistance in The Philippines.
abstract: From 1994 through 1996-1997, high-level ciprofloxacin resistance (minimum inhibitory concentration [MIC], > or = 4.0 microg/mL) increased from 9% to 49% of gonococcal isolates recovered from consecutive female sex workers in Cebu and Manila, The Philippines (P < .01). During 1996-1997, 105 female sex workers with gonorrhea were prospectively randomized to receive treatment with oral ciprofloxacin, 500 mg, or cefixime, 400 mg, and followed for test of cure. Neisseria gonorrhoeae was reisolated within 28 days after treatment from 1 (3.8%) of 26 women given cefixime versus 24 (32.3%) of 72 women given ciprofloxacin (P < .01). Treatment failure (reisolation of pretreatment auxotype/serovar) occurred in 14 (46.7%) of 30 women infected with strains with MICs of ciprofloxacin > or = 4.0 microg/mL versus 1 (3.6%) of 28 infected by strains with MICs < 4.0 microg/mL (P < .01). High-level, clinically significant gonococcal resistance to ciprofloxacin has rapidly emerged in The Philippines, and spread of fluoroquinolone resistance through commercial sex poses a threat to control of gonorrhea and prevention of human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
authors: Research Institute of Tropical Medicine, Alabang, Muntinlupa City, The Philippines.
authors: M R
authors: MR
authors: Aplasca De Los Reyes
authors: V
authors: V
authors: Pato-Mesola
authors: J D
authors: JD
authors: Klausner
authors: R
authors: R
authors: Manalastas
authors: T
authors: T
authors: Wi
authors: C U
authors: CU
authors: Tuazon
authors: G
authors: G
authors: Dallabetta
authors: W L
authors: WL
authors: Whittington
authors: K K
authors: KK
authors: Holmes
mesh_terms: D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D020682:Cefixime / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D002939:Ciprofloxacin / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D006801:Humans; D009344:Neisseria gonorrhoeae / Q000187:drug effects / Q000302:isolation & purification; D010679:Philippines / Q000453:epidemiology; D011446:Prospective Studies; D011477:Sex Work; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D002511:Cephalosporins; D002939:Ciprofloxacin; D020682:Cefixime